First approved gene therapy for a hereditary eye disease carried out in Germany

Beitrag teilen

A large number of genes are associated with retinal diseases. RPE65-associated retinal dystrophies are a clinically heterogeneous group of hereditary retinal diseases that have in common a progressive decline in retinal function. Affected persons suffer from retinal degeneration which leads to a loss of visual field and visual acuity up to blindness.

The new therapy marks the beginning of a new era in ophthalmology. „Finally, a new treatment option can be offered to patients suffering from a previously untreatable retinal disease,“ said Professor Siegfried Priglinger, Director of the Eye Clinic.

contact for scientific information:
Professor Dr. Siegfried Priglinger
Director of the Department of Ophthalmology
University Hospital of LMU Munich
Mathildenstrasse 8, 80336 Munich, Germany

Please direct enquiries to

PD Dr. Claudia Priglinger
claudia.priglinger@med.uni-muenchen.de

Maximilian Gerhardt
maximilian.gerhardt@med.uni-muenchen.de

Prof. Dr. Günther Rudolph
guenther.rudolph@med.uni-muenchen.de

idw 2019/06
Beitrag teilen
Anzeige

Diese Website nutzt Cookies um bestmögliche Funktionalität bieten zu können. Finden Sie weitere Infos in unserer Datenschutzerklärung. Zur Datenschutzerklärung